Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Sep;23(5):463-8.
doi: 10.1097/CCO.0b013e328349428d.

Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities

Susan E Krown  1
Affiliations
Review

Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities

Susan E Krown. Curr Opin Oncol. 2011 Sep.

Abstract

Purpose of review: The purpose of this review is to summarize recent published literature on treatment of AIDS-associated Kaposi sarcoma, the most common HIV-associated malignancy and a leading cancer diagnosis in sub-Saharan Africa (SSA), and to highlight the challenges faced in treating Kaposi sarcoma in this resource-limited environment.

Recent findings: There are few prospective clinical trials for Kaposi sarcoma treatment in SSA, along with a relatively poor cancer treatment infrastructure, leading to late diagnosis and poor access to therapy. The only prospectively randomized trial of chemotherapy compared antiretroviral therapy (HAART) alone to HAART with combination chemotherapy with doxorubicin, bleomycin and vincristine (ABV), and documented a significantly higher rate of tumor regression for the combination along with improvement in quality of life and no adverse effects on HIV control. Other studies suggest that gemcitabine may be an active second-line chemotherapeutic agent after failure of HAART and ABV and suggest that AIDS-associated Kaposi sarcoma in children may respond well to HAART with chemotherapy. There are also (primarily retrospective) data suggesting a beneficial effect of HAART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as a manifestation of immune reconstitution inflammatory syndrome.

Summary: Opportunities and need exist for prospective research to establish evidence-based guidelines for the most effective treatments for Kaposi sarcoma in SSA.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bagni R, Whitby D. Kaposi’s sarcoma-associated herpesvirus transmission and primary infection. Curr Opin HIV AIDS. 2009;4:22–26. - PubMed
    1. Mosam A, Aboobaker J, Shaik F. Kaposi’s sarcoma in sub-Saharan Africa: a current perspective. Curr Opin Infect Dis. 2010;23:119–123. - PubMed
    1. Biryahwaho B, Dollard SC, Pfeiffer RM, et al. Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda. J Infect Dis. 2010;202:1347–1353. - PMC - PubMed
    1. Malope-Kgokong BI, Macphail P, Mbisa G, et al. Kaposi's sarcoma associated-herpes virus (KSHV) seroprevalence in pregnant women in South Africa. Infect Agent Cancer. 2010;5:14. - PMC - PubMed
    1. Caterino-de-Araujo A, Manuel RC, Del Bianco R, et al. Seroprevalence of human herpesvirus 8 infection in individuals from health care centers in Mozambique: potential for endemic and epidemic Kaposi's sarcoma. J Med Virol. 2010;82:1216–1223. - PubMed

Publication types

MeSH terms